{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:30:41Z","timestamp":1787898641229,"version":"build-2784847793"},"reference-count":239,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["Marie Sk\u0142odowska-Curie Actions grant agreement No.721906-TRACT"],"award-info":[{"award-number":["Marie Sk\u0142odowska-Curie Actions grant agreement No.721906-TRACT"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protein J"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10930-024-10237-6","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:49:00Z","timestamp":1731336540000},"page":"1-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibody Aggregation: A Problem Within the Biopharmaceutical Industry and Its Role in AL Amyloidosis Disease"],"prefix":"10.1007","volume":"44","author":[{"given":"Kate","family":"Sheehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad C.","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-057X","authenticated-orcid":false,"given":"Jerrard M.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3663-2002","authenticated-orcid":false,"given":"K. H.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"10237_CR1","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM (2023) Antibodies to watch in 2023. MAbs 15:2153410","journal-title":"MAbs"},{"key":"10237_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/HAB-211513","volume":"30","author":"Y El Abd","year":"2022","unstructured":"El Abd Y, Tabll A, Smolic R, Smolic M (2022) Mini-review: the market growth of diagnostic and therapeutic monoclonal antibodies\u2014SARS CoV-2 as an example. Hum Antibodies 30:15\u201324","journal-title":"Hum Antibodies"},{"key":"10237_CR3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J (2023) Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs 83:569\u2013576","journal-title":"Drugs"},{"key":"10237_CR4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527","journal-title":"JAMA"},{"key":"10237_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.copbio.2014.08.001","volume":"30","author":"CJ Roberts","year":"2014","unstructured":"Roberts CJ (2014) Protein aggregation and its impact on product quality. Curr Opin Biotechnol 30:211\u2013217","journal-title":"Curr Opin Biotechnol"},{"key":"10237_CR6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","volume":"105","author":"EM Moussa","year":"2016","unstructured":"Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM (2016) Immunogenicity of therapeutic protein aggregates. J Pharm Sci 105:417\u2013430","journal-title":"J Pharm Sci"},{"key":"10237_CR7","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","volume":"8","author":"AS Rosenberg","year":"2006","unstructured":"Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. Aaps j 8:E501\u2013E507","journal-title":"Aaps j"},{"key":"10237_CR8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","volume":"32","author":"M Ahmadi","year":"2015","unstructured":"Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S, Hawe A, Jiskoot W, Baker MP, Fogg MH (2015) Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res 32:1383\u20131394","journal-title":"Pharm Res"},{"key":"10237_CR9","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","volume":"287","author":"MK Joubert","year":"2012","unstructured":"Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287:25266\u201325279","journal-title":"J Biol Chem"},{"key":"10237_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4161\/mabs.1.5.9631","volume":"1","author":"Y Luo","year":"2009","unstructured":"Luo Y, Lu Z, Raso SW, Entrican C, Tangarone B (2009) Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors. MAbs 1:491\u2013504","journal-title":"MAbs"},{"key":"10237_CR11","doi-asserted-by":"crossref","first-page":"e86322","DOI":"10.1371\/journal.pone.0086322","volume":"9","author":"V Rombach-Riegraf","year":"2014","unstructured":"Rombach-Riegraf V, Karle AC, Wolf B, Sord\u00e9 L, Koepke S, Gottlieb S, Krieg J, Djidja MC, Baban A, Spindeldreher S, Koulov AV, Kiessling A (2014) Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS ONE 9:e86322","journal-title":"PLoS ONE"},{"key":"10237_CR12","volume-title":"Amyloidosis in StatPearls, StatPearls Publishing Copyright \u00a9 2023","author":"JG Bustamante","year":"2023","unstructured":"Bustamante JG, S Z (2023) Amyloidosis in StatPearls, StatPearls Publishing Copyright \u00a9 2023. StatPearls Publishing LLC, Treasure Island"},{"key":"10237_CR13","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkenheim A, Szab\u00f3 B, Sztaniszl\u00e1v \u00c1J (2020) Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation. BMJ Case Rep 13","DOI":"10.1136\/bcr-2019-232756"},{"key":"10237_CR14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","volume":"187","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A (2019) Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol 187:588\u2013594","journal-title":"Br J Haematol"},{"key":"10237_CR15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/80816","volume":"1","author":"E Meffre","year":"2000","unstructured":"Meffre E, Casellas R, Nussenzweig MC (2000) Antibody regulation of B cell development. Nat Immunol 1:379\u2013385","journal-title":"Nat Immunol"},{"key":"10237_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4939-2999-3_2","volume":"1348","author":"H Ma","year":"2015","unstructured":"Ma H, O\u2019Kennedy R (2015) The structure of natural and recombinant antibodies. Methods Mol Biol 1348:7\u201311","journal-title":"Methods Mol Biol"},{"key":"10237_CR17","doi-asserted-by":"crossref","unstructured":"Stanfield RL, Wilson IA (2014) Antibody structure. Microbiol Spectr 2","DOI":"10.1128\/microbiolspec.AID-0012-2013"},{"key":"10237_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","volume":"25","author":"JN Arnold","year":"2007","unstructured":"Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21\u201350","journal-title":"Annu Rev Immunol"},{"key":"10237_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/glycob\/cwaa018","volume":"30","author":"EB Irvine","year":"2020","unstructured":"Irvine EB, Alter G (2020) Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology 30:241\u2013253","journal-title":"Glycobiology"},{"key":"10237_CR20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/138920109788488932","volume":"10","author":"J Philo","year":"2009","unstructured":"Philo J, Arakawa T (2009) Mechanisms of protein aggregation. Curr Pharm Biotechnol 10:348\u2013351","journal-title":"Curr Pharm Biotechnol"},{"key":"10237_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0076-6879(06)13004-9","volume":"413","author":"G Marcon","year":"2006","unstructured":"Marcon G, Plakoutsi G, Chiti F (2006) Protein aggregation starting from the native globular state. Methods Enzymol 413:75\u201391","journal-title":"Methods Enzymol"},{"key":"10237_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/B978-0-12-386931-9.00003-9","volume":"117","author":"B Bolognesi","year":"2013","unstructured":"Bolognesi B, Tartaglia GG (2013) Physicochemical principles of protein aggregation. Prog Mol Biol Transl Sci 117:53\u201372","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10237_CR23","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1021\/bi00772a001","volume":"11","author":"AH Pekar","year":"1972","unstructured":"Pekar AH, Frank BH (1972) Conformation of proinsulin: a comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 11:4013\u20134016","journal-title":"Biochemistry"},{"key":"10237_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","volume":"390","author":"W Wang","year":"2010","unstructured":"Wang W, Nema S, Teagarden D (2010) Protein aggregation\u2014Pathways and influencing factors. Int J Pharm 390:89\u201399","journal-title":"Int J Pharm"},{"key":"10237_CR25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.xphs.2016.11.021","volume":"106","author":"ML Fleischman","year":"2017","unstructured":"Fleischman ML, Chung J, Paul EP, Lewus RA (2017) Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies. J Pharm Sci 106:994\u20131000","journal-title":"J Pharm Sci"},{"key":"10237_CR26","doi-asserted-by":"crossref","first-page":"24554","DOI":"10.1038\/srep24554","volume":"6","author":"AJ Weids","year":"2016","unstructured":"Weids AJ, Ibstedt S, Tam\u00e1s MJ, Grant CM (2016) Distinct stress conditions result in aggregation of proteins with similar properties. Sci Rep 6:24554","journal-title":"Sci Rep"},{"key":"10237_CR27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-4682-7-19","volume":"7","author":"VV Matveev","year":"2010","unstructured":"Matveev VV (2010) Native aggregation as a cause of origin of temporary cellular structures needed for all forms of cellular activity, signaling and transformations. Theor Biol Med Model 7:19","journal-title":"Theor Biol Med Model"},{"key":"10237_CR28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12551-017-0374-3","volume":"10","author":"S Uchiyama","year":"2018","unstructured":"Uchiyama S, Noda M, Krayukhina E (2018) Sedimentation velocity analytical ultracentrifugation for characterization of therapeutic antibodies. Biophys Rev 10:259\u2013269","journal-title":"Biophys Rev"},{"key":"10237_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/19420862.2015.1112477","volume":"8","author":"F Courtois","year":"2016","unstructured":"Courtois F, Agrawal NJ, Lauer TM, Trout BL (2016) Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs 8:99\u2013112","journal-title":"MAbs"},{"key":"10237_CR30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pro.309","volume":"19","author":"CB Andersen","year":"2010","unstructured":"Andersen CB, Manno M, Rischel C, Th\u00f3r\u00f3lfsson M, Martorana V (2010) Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci 19:279\u2013290","journal-title":"Protein Sci"},{"key":"10237_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pharma.2009.05.008","volume":"67","author":"A Lahlou","year":"2009","unstructured":"Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A (2009) Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr 67:340\u2013352","journal-title":"Ann Pharm Fr"},{"key":"10237_CR32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4161\/mabs.1.2.7632","volume":"1","author":"B Demeule","year":"2009","unstructured":"Demeule B, Palais C, Machaidze G, Gurny R, Arvinte T (2009) New methods allowing the detection of protein aggregates: a case study on trastuzumab. MAbs 1:142\u2013150","journal-title":"MAbs"},{"key":"10237_CR33","doi-asserted-by":"crossref","first-page":"15485","DOI":"10.1038\/srep15485","volume":"5","author":"E Chatani","year":"2015","unstructured":"Chatani E, Inoue R, Imamura H, Sugiyama M, Kato M, Yamamoto M, Nishida K, Kanaya T (2015) Early aggregation preceding the nucleation of insulin amyloid fibrils as monitored by small angle X-ray scattering. Sci Rep 5:15485","journal-title":"Sci Rep"},{"key":"10237_CR34","doi-asserted-by":"crossref","unstructured":"Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov DS (2016) Antibody aggregation: insights from sequence and structure. Antibodies (Basel) 5","DOI":"10.3390\/antib5030019"},{"key":"10237_CR35","doi-asserted-by":"crossref","unstructured":"Zheng K, Ren D, Wang YJ, Lilyestrom W, Scherer T, Hong JKY, Ji JA (2021) Monoclonal antibody aggregation associated with free radical induced oxidation. Int J Mol Sci 22","DOI":"10.3390\/ijms22083952"},{"key":"10237_CR36","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1021\/ac062311j","volume":"79","author":"Z Wei","year":"2007","unstructured":"Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA (2007) Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem 79:2797\u20132805","journal-title":"Anal Chem"},{"key":"10237_CR37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2006.11.050","volume":"850","author":"C Chumsae","year":"2007","unstructured":"Chumsae C, Gaza-Bulseco G, Sun J, Liu H (2007) Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 850:285\u2013294","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10237_CR38","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","volume":"111","author":"S Gupta","year":"2022","unstructured":"Gupta S, Jiskoot W, Sch\u00f6neich C, Rathore AS (2022) Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and Efficacy. J Pharm Sci 111:903\u2013918","journal-title":"J Pharm Sci"},{"key":"10237_CR39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1110\/ps.035410.108","volume":"17","author":"T Takata","year":"2008","unstructured":"Takata T, Oxford JT, Demeler B, Lampi KJ (2008) Deamidation destabilizes and triggers aggregation of a lens protein, betaA3-crystallin. Protein Sci 17:1565\u20131575","journal-title":"Protein Sci"},{"key":"10237_CR40","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1021\/acs.molpharmaceut.8b01311","volume":"16","author":"ME Alam","year":"2019","unstructured":"Alam ME, Barnett GV, Slaney TR, Starr CG, Das TK, Tessier PM (2019) Deamidation can compromise antibody colloidal stability and enhance aggregation in a pH-dependent manner. Mol Pharm 16:1939\u20131949","journal-title":"Mol Pharm"},{"key":"10237_CR41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bpj.2010.11.041","volume":"100","author":"JD Schmit","year":"2011","unstructured":"Schmit JD, Ghosh K, Dill K (2011) What drives amyloid molecules to assemble into oligomers and fibrils? Biophys J 100:450\u2013458","journal-title":"Biophys J"},{"key":"10237_CR42","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1529\/biophysj.106.094342","volume":"92","author":"MR Krebs","year":"2007","unstructured":"Krebs MR, Devlin GL, Donald AM (2007) Protein particulates: another generic form of protein aggregation? Biophys J 92:1336\u20131342","journal-title":"Biophys J"},{"key":"10237_CR43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/pro.3674","volume":"28","author":"AK Srivastava","year":"2019","unstructured":"Srivastava AK, Pittman JM, Zerweck J, Venkata BS, Moore PC, Sachleben JR, Meredith SC (2019) \u03b2-Amyloid aggregation and heterogeneous nucleation. Protein Sci 28:1567\u20131581","journal-title":"Protein Sci"},{"key":"10237_CR44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jps.20237","volume":"94","author":"EY Chi","year":"2005","unstructured":"Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW (2005) Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256\u2013274","journal-title":"J Pharm Sci"},{"key":"10237_CR45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","volume":"390","author":"W Wang","year":"2010","unstructured":"Wang W, Nema S, Teagarden D (2010) Protein aggregation\u2014Pathways and influencing factors. Intl J Pharmaceutics 390:89\u201399","journal-title":"Intl J Pharmaceutics"},{"key":"10237_CR46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","volume":"100","author":"V Perfetti","year":"2002","unstructured":"Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G (2002) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100:948\u2013953","journal-title":"Blood"},{"key":"10237_CR47","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520\u20132530","journal-title":"Blood"},{"key":"10237_CR48","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1529\/biophysj.106.098608","volume":"92","author":"CC Lee","year":"2007","unstructured":"Lee CC, Nayak A, Sethuraman A, Belfort G, McRae GJ (2007) A three-stage kinetic model of amyloid fibrillation. Biophys J 92:3448\u20133458","journal-title":"Biophys J"},{"key":"10237_CR49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1134\/S0026893315020065","volume":"49","author":"AA Kulikova","year":"2015","unstructured":"Kulikova AA, Makarov AA, Kozin SA (2015) The role of zinc ions and structural polymorphism of \u03b2-amyloid in the Alzheimer\u2019s disease initiation. Mol Biol (Mosk) 49:249\u2013263","journal-title":"Mol Biol (Mosk)"},{"key":"10237_CR50","doi-asserted-by":"crossref","first-page":"12568","DOI":"10.1021\/acs.jpcb.5b05799","volume":"119","author":"JA Luiken","year":"2015","unstructured":"Luiken JA, Bolhuis PG (2015) Primary nucleation kinetics of short fibril-forming amyloidogenic peptides. J Phys Chem B 119:12568\u201312579","journal-title":"J Phys Chem B"},{"key":"10237_CR51","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1039\/C4CP05563B","volume":"17","author":"P Arosio","year":"2015","unstructured":"Arosio P, Knowles TP, Linse S (2015) On the lag phase in amyloid fibril formation. Phys Chem Chem Phys 17:7606\u20137618","journal-title":"Phys Chem Chem Phys"},{"key":"10237_CR52","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.1039\/C8CC02204F","volume":"54","author":"M T\u00f6rnquist","year":"2018","unstructured":"T\u00f6rnquist M, Michaels TCT, Sanagavarapu K, Yang X, Meisl G, Cohen SIA, Knowles TPJ, Linse S (2018) Secondary nucleation in amyloid formation. Chem Commun (Camb) 54:8667\u20138684","journal-title":"Chem Commun (Camb)"},{"key":"10237_CR53","doi-asserted-by":"crossref","unstructured":"Almeida ZL, Brito RMM (2020) Structure and aggregation mechanisms in amyloids. Molecules 25","DOI":"10.3390\/molecules25051195"},{"key":"10237_CR54","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jpcb.5b01160","volume":"119","author":"L Nicoud","year":"2015","unstructured":"Nicoud L, Lazzari S, Balderas Barrag\u00e1n D, Morbidelli M (2015) Fragmentation of amyloid fibrils occurs in preferential positions depending on the environmental conditions. J Phys Chem B 119:4644\u20134652","journal-title":"J Phys Chem B"},{"key":"10237_CR55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","volume":"29","author":"C Galeotti","year":"2017","unstructured":"Galeotti C, Kaveri SV, Bayry J (2017) IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 29:491\u2013498","journal-title":"Int Immunol"},{"key":"10237_CR56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","volume":"81","author":"Y Xie","year":"2020","unstructured":"Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, Yang L, Fu S, Wang R (2020) Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 81:318\u2013356","journal-title":"J Infect"},{"key":"10237_CR57","doi-asserted-by":"crossref","first-page":"627844","DOI":"10.3389\/fimmu.2021.627844","volume":"12","author":"W Cao","year":"2021","unstructured":"Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L, Li T (2021) High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China. Front Immunol 12:627844","journal-title":"Front Immunol"},{"key":"10237_CR58","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/jmv.26727","volume":"93","author":"P Moradimajd","year":"2021","unstructured":"Moradimajd P, Samaee H, Sedigh-Maroufi S, Kourosh-Aami M, Mohsenzadagan M (2021) Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence. J Med Virol 93:2675\u20132682","journal-title":"J Med Virol"},{"key":"10237_CR59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","volume":"68","author":"EJ Cohn","year":"1946","unstructured":"Cohn EJ, Strong LE et al (1946) Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68:459\u2013475","journal-title":"J Am Chem Soc"},{"key":"10237_CR60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","volume":"71","author":"JL Oncley","year":"1949","unstructured":"Oncley JL, Melin M et al (1949) The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. J Am Chem Soc 71:541\u2013550","journal-title":"J Am Chem Soc"},{"key":"10237_CR61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15171\/ijb.1401","volume":"14","author":"K Mousavi Hosseini","year":"2016","unstructured":"Mousavi Hosseini K, Ghasemzadeh M (2016) Implementation of plasma fractionation in biological medicines production. Iran J Biotechnol 14:213\u2013220","journal-title":"Iran J Biotechnol"},{"key":"10237_CR62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/clim.2001.5132","volume":"101","author":"S Razvi","year":"2001","unstructured":"Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C (2001) Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 101:284\u2013288","journal-title":"Clin Immunol"},{"key":"10237_CR63","first-page":"619","volume":"11","author":"IS Kim","year":"2001","unstructured":"Kim IS, Choi YW, Lee SR, Cho HB, Eo HG, Woo HS, Chang CE (2001) Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. J Microbiol Biotechnol 11:619\u2013627","journal-title":"J Microbiol Biotechnol"},{"key":"10237_CR64","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/trf.13619","volume":"56","author":"Y-T Hsieh","year":"2016","unstructured":"Hsieh Y-T, Mullin L, Greenhalgh P, Cunningham M, Goodrich E, Shea J, Youssef E, Burnouf T (2016) Single-use technology for solvent\/detergent virus inactivation of industrial plasma products. Transfusion 56:1384\u20131393","journal-title":"Transfusion"},{"key":"10237_CR65","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/trf.13030","volume":"55","author":"SD Keil","year":"2015","unstructured":"Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L, Gilmour D, Duverlie G, Goodrich RP (2015) Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 55:1736\u20131744","journal-title":"Transfusion"},{"key":"10237_CR66","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/trf.16022","volume":"60","author":"NJ Roth","year":"2020","unstructured":"Roth NJ, Dichtelm\u00fcller HO, Fabbrizzi F, Flechsig E, Gr\u00f6ner A, Gustafson M, Jorquera JI, Kreil TR, Misztela D, Moretti E, Moscardini M, Poelsler G, More J, Roberts P, Wieser A, Gajardo R (2020) Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years\u02bc experience of the plasma protein manufacturers. Transfusion 60:2661\u20132674","journal-title":"Transfusion"},{"key":"10237_CR67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/trf.14390","volume":"58","author":"A Gr\u00f6ner","year":"2018","unstructured":"Gr\u00f6ner A, Broumis C, Fang R, Nowak T, Popp B, Sch\u00e4fer W, Roth NJ (2018) Effective inactivation of a wide range of viruses by pasteurization. Transfusion 58:41\u201351","journal-title":"Transfusion"},{"key":"10237_CR68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43141-021-00264-6","volume":"19","author":"S Mitra","year":"2021","unstructured":"Mitra S, Tomar PC (2021) Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol 19:159","journal-title":"J Genet Eng Biotechnol"},{"key":"10237_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2013.521","volume":"134","author":"CM Hammers","year":"2014","unstructured":"Hammers CM, Stanley JR (2014) Antibody phage display: technique and applications. J Invest Dermatol 134:1\u20135","journal-title":"J Invest Dermatol"},{"key":"10237_CR70","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.it.2021.10.008","volume":"42","author":"A Pedrioli","year":"2021","unstructured":"Pedrioli A, Oxenius A (2021) Single B cell technologies for monoclonal antibody discovery. Trends Immunol 42:1143\u20131158","journal-title":"Trends Immunol"},{"key":"10237_CR71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256\u2013265","journal-title":"MAbs"},{"key":"10237_CR72","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.21104","volume":"97","author":"RM Ionescu","year":"2008","unstructured":"Ionescu RM, Vlasak J, Price C, Kirchmeier M (2008) Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414\u20131426","journal-title":"J Pharm Sci"},{"key":"10237_CR73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4161\/mabs.2.5.12720","volume":"2","author":"F Li","year":"2010","unstructured":"Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A (2010) Cell culture processes for monoclonal antibody production. MAbs 2:466\u2013479","journal-title":"MAbs"},{"key":"10237_CR74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/138920108786786367","volume":"9","author":"M Chartrain","year":"2008","unstructured":"Chartrain M, Chu L (2008) Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol 9:447\u2013467","journal-title":"Curr Pharm Biotechnol"},{"key":"10237_CR75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s004490050319","volume":"16","author":"GL Prasanna","year":"1997","unstructured":"Prasanna GL, Panda T (1997) Electroporation: basic principles, practical considerations and applications in molecular biology. Bioprocess Eng 16:261\u2013264","journal-title":"Bioprocess Eng"},{"key":"10237_CR76","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","volume":"84","author":"PL Felgner","year":"1987","unstructured":"Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84:7413\u20137417","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chroma.2015.08.068","volume":"1415","author":"AR Mazzer","year":"2015","unstructured":"Mazzer AR, Perraud X, Halley J, O\u2019Hara J, Bracewell DG (2015) Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A 1415:83\u201390","journal-title":"J Chromatogr A"},{"key":"10237_CR78","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/ja206557y","volume":"134","author":"EP O\u2019Brien","year":"2012","unstructured":"O\u2019Brien EP, Brooks BR, Thirumalai D (2012) Effects of pH on proteins: predictions for ensemble and single-molecule pulling experiments. J Am Chem Soc 134:979\u2013987","journal-title":"J Am Chem Soc"},{"key":"10237_CR79","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1074\/jbc.M111.297697","volume":"287","author":"RF Latypov","year":"2012","unstructured":"Latypov RF, Hogan S, Lau H, Gadgil H, Liu D (2012) Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 287:1381\u20131396","journal-title":"J Biol Chem"},{"key":"10237_CR80","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejpb.2016.07.020","volume":"107","author":"F Bickel","year":"2016","unstructured":"Bickel F, Herold EM, Signes A, Romeijn S, Jiskoot W, Kiefer H (2016) Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation. Eur J Pharm Biopharm 107:310\u2013320","journal-title":"Eur J Pharm Biopharm"},{"key":"10237_CR81","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11095-012-0965-4","volume":"30","author":"S Saito","year":"2013","unstructured":"Saito S, Hasegawa J, Kobayashi N, Tomitsuka T, Uchiyama S, Fukui K (2013) Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: influence of colloidal and conformational stabilities. Pharm Res 30:1263\u20131280","journal-title":"Pharm Res"},{"key":"10237_CR82","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4161\/mabs.2.5.12645","volume":"2","author":"HF Liu","year":"2010","unstructured":"Liu HF, Ma J, Winter C, Bayer R (2010) Recovery and purification process development for monoclonal antibody production. MAbs 2:480\u2013499","journal-title":"MAbs"},{"key":"10237_CR83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","volume":"21","author":"RC Monteiro","year":"2003","unstructured":"Monteiro RC, Van De Winkel JG (2003) IgA Fc receptors. Annu Rev Immunol 21:177\u2013204","journal-title":"Annu Rev Immunol"},{"key":"10237_CR84","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2019.00553","volume":"10","author":"A Breedveld","year":"2019","unstructured":"Breedveld A, van Egmond M (2019) IgA and Fc\u03b1RI: pathological roles and therapeutic opportunities. Front Immunol 10:553","journal-title":"Front Immunol"},{"key":"10237_CR85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2015.09.005","volume":"68","author":"JH Leusen","year":"2015","unstructured":"Leusen JH (2015) IgA as therapeutic antibody. Mol Immunol 68:35\u201339","journal-title":"Mol Immunol"},{"key":"10237_CR86","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2011.061408","volume":"97","author":"V Pascal","year":"2012","unstructured":"Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, Imbertie L, Pangault C, Tarte K, Tiraby G, Cogn\u00e9 M (2012) Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica 97:1686\u20131694","journal-title":"Haematologica"},{"key":"10237_CR87","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/emmm.201201929","volume":"5","author":"P Boross","year":"2013","unstructured":"Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH (2013) IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 5:1213\u20131226","journal-title":"EMBO Mol Med"},{"key":"10237_CR88","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/19420862.2015.1106658","volume":"8","author":"S Meyer","year":"2016","unstructured":"Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH (2016) Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs 8:87\u201398","journal-title":"MAbs"},{"key":"10237_CR89","doi-asserted-by":"crossref","first-page":"974854","DOI":"10.3389\/fchem.2022.974854","volume":"10","author":"L Ding","year":"2022","unstructured":"Ding L, Chen X, Cheng H, Zhang T, Li Z (2022) Advances in IgA glycosylation and its correlation with diseases. Front Chem 10:974854","journal-title":"Front Chem"},{"key":"10237_CR90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/19420862.2015.1102812","volume":"8","author":"GJ Rouwendal","year":"2016","unstructured":"Rouwendal GJ, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JH, Boross P, Wuhrer M, Verheijden GF, Dokter WH, Timmers M, Ubink R (2016) A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs 8:74\u201386","journal-title":"MAbs"},{"key":"10237_CR91","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150551","author":"X Xie","year":"2021","unstructured":"Xie X, Gao L, Liu P, Lv J, Lu WH, Zhang H, Jin J (2021) Propensity of IgA to self-aggregate via tailpiece cysteine-471 and treatment of IgA nephropathy using cysteamine. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.150551","journal-title":"JCI Insight"},{"key":"10237_CR92","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4161\/mabs.26396","volume":"5","author":"C Brunke","year":"2013","unstructured":"Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T (2013) Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs 5:936\u2013945","journal-title":"MAbs"},{"key":"10237_CR93","doi-asserted-by":"crossref","unstructured":"Emami F, Vatanara A, Park EJ, Na DH (2018) Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics 10","DOI":"10.3390\/pharmaceutics10030131"},{"key":"10237_CR94","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0605504103","volume":"103","author":"HJ Dyson","year":"2006","unstructured":"Dyson HJ, Wright PE, Scheraga HA (2006) The role of hydrophobic interactions in initiation and propagation of protein folding. Proc Natl Acad Sci 103:13057","journal-title":"Proc Natl Acad Sci"},{"key":"10237_CR95","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1208\/ps050210","volume":"5","author":"JD Andya","year":"2003","unstructured":"Andya JD, Hsu CC, Shire SJ (2003) Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5:E10","journal-title":"AAPS PharmSci"},{"key":"10237_CR96","volume-title":"Impact of Manufacturing-scale freeze-thaw conditions on a mAb solution","author":"JM Peter","year":"2017","unstructured":"Peter JM, James DC, Pruett WA, Douglas PN, Kashappa Goud D (2017) Impact of Manufacturing-scale freeze-thaw conditions on a mAb solution. BioPharm International"},{"key":"10237_CR97","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-010-0343-z","volume":"28","author":"SK Singh","year":"2011","unstructured":"Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M (2011) Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res 28:873\u2013885","journal-title":"Pharm Res"},{"key":"10237_CR98","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/s41598-018-37072-x","volume":"9","author":"N Bai","year":"2019","unstructured":"Bai N, Roder H, Dickson A, Karanicolas J (2019) Isothermal analysis of ThermoFluor data can readily provide quantitative binding affinities. Sci Rep 9:2650","journal-title":"Sci Rep"},{"key":"10237_CR99","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/mp400666b","volume":"12","author":"ML Brader","year":"2015","unstructured":"Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM (2015) Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm 12:1005\u20131017","journal-title":"Mol Pharm"},{"key":"10237_CR100","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/jps.21955","volume":"99","author":"F He","year":"2010","unstructured":"He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI (2010) High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99:1707\u20131720","journal-title":"J Pharm Sci"},{"key":"10237_CR101","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1087057114557781","volume":"20","author":"A Niedziela-Majka","year":"2015","unstructured":"Niedziela-Majka A, Kan E, Weissburg P, Mehra U, Sellers S, Sakowicz R (2015) High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody. J Biomol Screening 20:552\u2013559","journal-title":"J Biomol Screening"},{"key":"10237_CR102","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/open.201900167","volume":"8","author":"T Zhang","year":"2019","unstructured":"Zhang T, Nagel-Steger L, Willbold D (2019) Solution-based determination of dissociation constants for the binding of Abeta42 to antibodies. ChemistryOpen 8:989\u2013994","journal-title":"ChemistryOpen"},{"key":"10237_CR103","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0297-1","volume":"28","author":"J den Engelsman","year":"2011","unstructured":"den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28:920\u2013933","journal-title":"Pharm Res"},{"key":"10237_CR104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jpba.2010.01.014","volume":"52","author":"R Tantipolphan","year":"2010","unstructured":"Tantipolphan R, Romeijn S, Engelsman J, Torosantucci R, Rasmussen T, Jiskoot W (2010) Elution behavior of insulin on high-performance size exclusion chromatography at neutral pH. J Pharm Biomed Anal 52:195\u2013202","journal-title":"J Pharm Biomed Anal"},{"key":"10237_CR105","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s11095-011-0416-7","volume":"28","author":"P Arosio","year":"2011","unstructured":"Arosio P, Barolo G, Muller-Spath T, Wu H, Morbidelli M (2011) Aggregation stability of a monoclonal antibody during downstream processing. Pharm Res 28:1884\u20131894","journal-title":"Pharm Res"},{"key":"10237_CR106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2014.04.011","volume":"101","author":"S Fekete","year":"2014","unstructured":"Fekete S, Beck A, Veuthey J-L, Guillarme D (2014) Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal 101:161\u2013173","journal-title":"J Pharm Biomed Anal"},{"key":"10237_CR107","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0003-2697(82)90102-6","volume":"126","author":"W Kopaciewicz","year":"1982","unstructured":"Kopaciewicz W, Regnier FE (1982) Nonideal size-exclusion chromatography of proteins: effects of pH at low ionic strength. Anal Biochem 126:8\u201316","journal-title":"Anal Biochem"},{"key":"10237_CR108","doi-asserted-by":"crossref","first-page":"E564","DOI":"10.1208\/aapsj080365","volume":"8","author":"JS Philo","year":"2006","unstructured":"Philo JS (2006) Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564\u2013E571","journal-title":"AAPS J"},{"key":"10237_CR109","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jps.21857","volume":"99","author":"R Yumioka","year":"2010","unstructured":"Yumioka R, Sato H, Tomizawa H, Yamasaki Y, Ejima D (2010) Mobile phase containing arginine provides more reliable SEC condition for aggregation analysis. J Pharm Sci 99:618\u2013620","journal-title":"J Pharm Sci"},{"key":"10237_CR110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/138920109788488815","volume":"10","author":"JS Philo","year":"2009","unstructured":"Philo JS (2009) A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359\u2013372","journal-title":"Curr Pharm Biotechnol"},{"key":"10237_CR111","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ab.2007.04.035","volume":"367","author":"A Pekar","year":"2007","unstructured":"Pekar A, Sukumar M (2007) Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: practical considerations that affect precision and accuracy. Anal Biochem 367:225\u2013237","journal-title":"Anal Biochem"},{"key":"10237_CR112","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/jps.21654","volume":"98","author":"K Arthur","year":"2009","unstructured":"Arthur K, Gabrielson J, Kendrick B, Stoner M (2009) Detection of protein aggregates by sedimentation velocity analytical ultracentrifugation (SV-AUC): sources of variability and their relative importance. J Pharm Sci 98:3522\u20133539","journal-title":"J Pharm Sci"},{"key":"10237_CR113","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ab.2009.09.036","volume":"396","author":"JP Gabrielson","year":"2010","unstructured":"Gabrielson JP, Arthur KK, Stoner MR, Winn BC, Kendrick BS, Razinkov V, Svitel J, Jiang Y, Voelker PJ, Fernandes CA, Ridgeway R (2010) Precision of protein aggregation measurements by sedimentation velocity analytical ultracentrifugation in biopharmaceutical applications. Anal Biochem 396:231\u2013241","journal-title":"Anal Biochem"},{"key":"10237_CR114","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0076-6879(09)63025-1","volume":"463","author":"JT McCue","year":"2009","unstructured":"McCue JT (2009) Theory and use of hydrophobic interaction chromatography in protein purification applications. Methods Enzymol 463:405\u2013414","journal-title":"Methods Enzymol"},{"key":"10237_CR115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejpb.2004.03.034","volume":"58","author":"W Fraunhofer","year":"2004","unstructured":"Fraunhofer W, Winter G (2004) The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm 58:369\u2013383","journal-title":"Eur J Pharm Biopharm"},{"key":"10237_CR116","doi-asserted-by":"crossref","unstructured":"Conner CG, McAndrew J, Menegotti S, Velev OD (2022) An accelerated antibody aggregation test based on time sequenced dynamic light scattering. Coll Surf A: Physicochem Eng Aspects 653","DOI":"10.1016\/j.colsurfa.2022.129833"},{"key":"10237_CR117","doi-asserted-by":"crossref","first-page":"1955810","DOI":"10.1080\/19420862.2021.1955810","volume":"13","author":"S Valtonen","year":"2021","unstructured":"Valtonen S, Vuorinen E, Eskonen V, Malakoutikhah M, Kopra K, H\u00e4rm\u00e4 H (2021) Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies. MAbs 13:1955810","journal-title":"MAbs"},{"key":"10237_CR118","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.febslet.2013.11.027","volume":"588","author":"H Zhang","year":"2014","unstructured":"Zhang H, Cui W, Gross ML (2014) Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies. FEBS Lett 588:308\u2013317","journal-title":"FEBS Lett"},{"key":"10237_CR119","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/acs.analchem.7b00464","volume":"89","author":"MB Taraban","year":"2017","unstructured":"Taraban MB, DePaz RA, Lobo B, Yu YB (2017) Water proton NMR: a tool for protein aggregation characterization. Anal Chem 89:5494\u20135502","journal-title":"Anal Chem"},{"key":"10237_CR120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cbic.201800631","volume":"20","author":"BT Falk","year":"2019","unstructured":"Falk BT, Liang Y, McCoy MA (2019) Diffusion profiling of therapeutic proteins by using solution NMR spectroscopy. ChemBioChem 20:896\u2013899","journal-title":"ChemBioChem"},{"key":"10237_CR121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/19420862.2018.1544454","volume":"11","author":"RG Brinson","year":"2019","unstructured":"Brinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, Gingras G, Ghasriani H, Aubin Y, Pierens GK, Jia X, Mobli M, Grant HG, Keizer DW, Schweimer K, Stahle J, Widmalm G, Zartler ER, Lawrence CW, Reardon PN, Cort JR, Xu P, Ni F, Yanaka S, Kato K, Parnham SR, Tsao D, Blomgren A, Rundlof T, Trieloff N, Schmieder P, Ross A, Skidmore K, Chen K, Keire D, Freedberg DI, Suter-Stahel T, Wider G, Ilc G, Plavec J, Bradley SA, Baldisseri DM, Sforca ML, Zeri ACM, Wei JY, Szabo CM, Amezcua CA, Jordan JB, Wikstrom M (2019) Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs 11:94\u2013105","journal-title":"MAbs"},{"key":"10237_CR122","doi-asserted-by":"crossref","first-page":"113841","DOI":"10.1016\/j.jpba.2020.113841","volume":"195","author":"S Joshi","year":"2021","unstructured":"Joshi S, Khatri LR, Kumar A, Rathore AS (2021) Monitoring size and oligomeric-state distribution of therapeutic mAbs by NMR and DLS: Trastuzumab as a case study. J Pharm Biomed Anal 195:113841","journal-title":"J Pharm Biomed Anal"},{"key":"10237_CR123","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1021\/acs.analchem.8b05733","volume":"91","author":"MB Taraban","year":"2019","unstructured":"Taraban MB, DePaz RA, Lobo B, Yu YB (2019) Use of water proton NMR to characterize protein aggregates: gauging the response and sensitivity. Anal Chem 91:4107\u20134115","journal-title":"Anal Chem"},{"key":"10237_CR124","doi-asserted-by":"crossref","unstructured":"Morris GA (2009) Diffusion-ordered spectroscopy. In: eMagRes, Harris RK, Wasylishen RI (eds)","DOI":"10.1002\/9780470034590.emrstm0119.pub2"},{"key":"10237_CR125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4939-9678-0_13","volume":"2039","author":"PS Kandiyal","year":"2019","unstructured":"Kandiyal PS, Kim JY, Fortunati DL, Mok KH (2019) Size determination of protein oligomers\/aggregates using diffusion NMR spectroscopy. Methods Mol Biol 2039:173\u2013183","journal-title":"Methods Mol Biol"},{"key":"10237_CR126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","volume":"38","author":"J Dantal","year":"2013","unstructured":"Dantal J (2013) Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 38:275\u2013284","journal-title":"Am J Nephrol"},{"key":"10237_CR127","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bpc.2014.12.003","volume":"197","author":"L Nicoud","year":"2015","unstructured":"Nicoud L, Cohrs N, Arosio P, Norrant E, Morbidelli M (2015) Effect of polyol sugars on the stabilization of monoclonal antibodies. Biophys Chem 197:40\u201346","journal-title":"Biophys Chem"},{"key":"10237_CR128","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bpj.2009.05.007","volume":"97","author":"EA Golovina","year":"2009","unstructured":"Golovina EA, Golovin AV, Hoekstra FA, Faller R (2009) Water replacement hypothesis in atomic detail\u2013factors determining the structure of dehydrated bilayer stacks. Biophys J 97:490\u2013499","journal-title":"Biophys J"},{"key":"10237_CR129","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/jps.22458","volume":"100","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Wang YJ (2011) Trehalose: current use and future applications. J Pharm Sci 100:2020\u20132053","journal-title":"J Pharm Sci"},{"key":"10237_CR130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pro.3","volume":"18","author":"NK Jain","year":"2009","unstructured":"Jain NK, Roy I (2009) Effect of trehalose on protein structure. Protein Sci 18:24\u201336","journal-title":"Protein Sci"},{"key":"10237_CR131","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1021\/acs.jctc.9b01071","volume":"16","author":"GI Olgenblum","year":"2020","unstructured":"Olgenblum GI, Sapir L, Harries D (2020) Properties of aqueous trehalose mixtures: glass transition and hydrogen bonding. J Chem Theory Comput 16:1249\u20131262","journal-title":"J Chem Theory Comput"},{"key":"10237_CR132","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.xphs.2017.11.015","volume":"107","author":"P St\u00e4rtzel","year":"2018","unstructured":"St\u00e4rtzel P (2018) Arginine as an excipient for protein freeze-drying: a mini review. J Pharm Sci 107:960\u2013967","journal-title":"J Pharm Sci"},{"key":"10237_CR133","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1208\/pt060223","volume":"6","author":"W Liu","year":"2005","unstructured":"Liu W, Wang DQ, Nail SL (2005) Freeze-drying of proteins from a sucrose-glycine excipient system: effect of formulation composition on the initial recovery of protein activity. AAPS PharmSciTech 6:E150\u2013E157","journal-title":"AAPS PharmSciTech"},{"key":"10237_CR134","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0003-2697(03)00059-9","volume":"316","author":"SE Bondos","year":"2003","unstructured":"Bondos SE, Bicknell A (2003) Detection and prevention of protein aggregation before, during, and after purification. Anal Biochem 316:223\u2013231","journal-title":"Anal Biochem"},{"key":"10237_CR135","doi-asserted-by":"crossref","first-page":"115575","DOI":"10.1016\/j.jpba.2023.115575","volume":"234","author":"P Kumari","year":"2023","unstructured":"Kumari P, Saldanha M, Jain R, Dandekar P (2023) Controlling monoclonal antibody aggregation during cell culture using medium additives facilitated by the monitoring of aggregation in cell culture matrix using size exclusion chromatography. J Pharm Biomed Anal 234:115575","journal-title":"J Pharm Biomed Anal"},{"key":"10237_CR136","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/bit.23155","volume":"108","author":"M V\u00e1zquez-Rey","year":"2011","unstructured":"V\u00e1zquez-Rey M, Lang DA (2011) Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 108:1494\u20131508","journal-title":"Biotechnol Bioeng"},{"key":"10237_CR137","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/03639045.2017.1278768","volume":"43","author":"Y Cui","year":"2017","unstructured":"Cui Y, Cui P, Chen B, Li S, Guan H (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 43:519\u2013530","journal-title":"Drug Dev Ind Pharm"},{"key":"10237_CR138","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/jz900338m","volume":"1","author":"P Sundaramurthi","year":"2010","unstructured":"Sundaramurthi P, Suryanarayanan R (2010) Trehalose crystallization during freeze-drying: implications on lyoprotection. J Phys Chem Lett 1:510\u2013514","journal-title":"J Phys Chem Lett"},{"key":"10237_CR139","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1023\/A:1012144810067","volume":"14","author":"SP Duddu","year":"1997","unstructured":"Duddu SP, Dal Monte PR (1997) Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res 14:591\u2013595","journal-title":"Pharm Res"},{"key":"10237_CR140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4161\/19420862.2014.985504","volume":"7","author":"P Nichols","year":"2015","unstructured":"Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ (2015) Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs 7:212\u2013230","journal-title":"MAbs"},{"key":"10237_CR141","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jmb.2017.03.014","volume":"429","author":"R van der Kant","year":"2017","unstructured":"van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, A\u00dffalg K, Baatsen P, Compernolle G, Gils A, Studts JM, Schulz P, Garidel P, Schymkowitz J, Rousseau F (2017) Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol 429:1244\u20131261","journal-title":"J Mol Biol"},{"key":"10237_CR142","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-chembioeng-060816-101404","volume":"8","author":"G Meric","year":"2017","unstructured":"Meric G, Robinson AS, Roberts CJ (2017) Driving forces for nonnative protein aggregation and approaches to predict aggregation-prone regions. Annu Rev Chem Biomol Eng 8:139\u2013159","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"10237_CR143","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/bib\/bbv082","volume":"17","author":"I Walsh","year":"2016","unstructured":"Walsh I, Pollastri G, Tosatto SC (2016) Correct machine learning on protein sequences: a peer-reviewing perspective. Brief Bioinform 17:831\u2013840","journal-title":"Brief Bioinform"},{"key":"10237_CR144","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4161\/mabs.1.3.8035","volume":"1","author":"X Wang","year":"2009","unstructured":"Wang X, Das TK, Singh SK, Kumar S (2009) Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. MAbs 1:254\u2013267","journal-title":"MAbs"},{"key":"10237_CR145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2174\/138920309789630534","volume":"10","author":"MV Trivedi","year":"2009","unstructured":"Trivedi MV, Laurence JS, Siahaan TJ (2009) The role of thiols and disulfides on protein stability. Curr Protein Pept Sci 10:614\u2013625","journal-title":"Curr Protein Pept Sci"},{"key":"10237_CR146","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/19420862.2017.1330734","volume":"9","author":"JL Spidel","year":"2017","unstructured":"Spidel JL, Albone EF, Cheng X, Vaessen B, Jacob S, Milinichik AZ, Verdi A, Kline JB, Grasso L (2017) Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins. MAbs 9:907\u2013915","journal-title":"MAbs"},{"key":"10237_CR147","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/protein\/gzs042","volume":"25","author":"JM Perchiacca","year":"2012","unstructured":"Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM (2012) Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 25:591\u2013601","journal-title":"Protein Eng Des Sel"},{"key":"10237_CR148","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1073\/pnas.052706099","volume":"99","author":"JS Richardson","year":"2002","unstructured":"Richardson JS, Richardson DC (2002) Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc Natl Acad Sci USA 99:2754\u20132759","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR149","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/biot.201000091","volume":"6","author":"V Kayser","year":"2011","unstructured":"Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL (2011) Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 6:38\u201344","journal-title":"Biotechnol J"},{"key":"10237_CR150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2016.01.005","volume":"100","author":"F Higel","year":"2016","unstructured":"Higel F, Seidl A, S\u00f6rgel F, Friess W (2016) N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and FC fusion proteins. Eur J Pharm Biopharm 100:94\u2013100","journal-title":"Eur J Pharm Biopharm"},{"key":"10237_CR151","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jmb.2012.01.027","volume":"417","author":"JV Schaefer","year":"2012","unstructured":"Schaefer JV, Pl\u00fcckthun A (2012) Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression. J Mol Biol 417:309\u2013335","journal-title":"J Mol Biol"},{"key":"10237_CR152","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4161\/mabs.3.6.17922","volume":"3","author":"K Zheng","year":"2011","unstructured":"Zheng K, Bantog C, Bayer R (2011) The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3:568\u2013576","journal-title":"MAbs"},{"key":"10237_CR153","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1073\/pnas.1307776110","volume":"110","author":"M Crispin","year":"2013","unstructured":"Crispin M (2013) Therapeutic potential of deglycosylated antibodies. Proc Natl Acad Sci USA 110:10059\u201310060","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR154","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-0716-1685-7_8","volume":"2370","author":"H Jeon","year":"2022","unstructured":"Jeon H, Hayes JM, Mok KH (2022) In silico analysis of therapeutic antibody aggregation and the influence of glycosylation. Methods Mol Biol 2370:169\u2013183","journal-title":"Methods Mol Biol"},{"key":"10237_CR155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2021.04.070","volume":"558","author":"K Oyama","year":"2021","unstructured":"Oyama K, Ohkuri T, Ochi J, Caaveiro JMM, Ueda T (2021) Abolition of aggregation of CH(2) domain of human IgG1 when combining glycosylation and protein stabilization. Biochem Biophys Res Commun 558:114\u2013119","journal-title":"Biochem Biophys Res Commun"},{"key":"10237_CR156","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/glycob\/cwy092","volume":"29","author":"R Mastrangeli","year":"2019","unstructured":"Mastrangeli R, Palinsky W, Bierau H (2019) Glycoengineered antibodies: towards the next-generation of immunotherapeutics. Glycobiology 29:199\u2013210","journal-title":"Glycobiology"},{"key":"10237_CR157","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/jb\/mvaa116","volume":"169","author":"H Nakamura","year":"2021","unstructured":"Nakamura H, Kiyoshi M, Anraku M, Hashii N, Oda-Ueda N, Ueda T, Ohkuri T (2021) Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted from Pichia pastoris. J Biochem 169:435\u2013443","journal-title":"J Biochem"},{"key":"10237_CR158","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, Shubin R, Wray S, Weiss MS, Bosco JA, Power SA, Mok K, Inglese M (2021) A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler 27:420\u2013429","journal-title":"Mult Scler"},{"key":"10237_CR159","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/febs.16390","volume":"290","author":"RM Absmeier","year":"2023","unstructured":"Absmeier RM, Rottenaicher GJ, Svilenov HL, Kazman P, Buchner J (2023) Antibodies gone bad\u2014the molecular mechanism of light chain amyloidosis. FEBS J 290:1398\u20131419","journal-title":"FEBS J"},{"key":"10237_CR160","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.hoc.2020.07.003","volume":"34","author":"GJ Morgan","year":"2020","unstructured":"Morgan GJ, Wall JS (2020) The process of amyloid formation due to monoclonal immunoglobulins. Hematol Oncol Clin North Am 34:1041\u20131054","journal-title":"Hematol Oncol Clin North Am"},{"key":"10237_CR161","first-page":"1518","volume":"13","author":"R Rios-Tamayo","year":"2023","unstructured":"Rios-Tamayo R, Krsnik I, Gomez-Bueno M, Garcia-Pavia P, Segovia-Cubero J, Huerta A, Salas C, Silvestre RA, Sanchez A, Manso M, Delgado L, Lahuerta JJ, Martinez-Lopez J, Duarte RF (2023) AL amyloidosis and multiple myeloma: a complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel) 13:1518","journal-title":"Life (Basel)"},{"key":"10237_CR162","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748","journal-title":"Leukemia"},{"key":"10237_CR163","doi-asserted-by":"crossref","first-page":"e5169","DOI":"10.1371\/journal.pone.0005169","volume":"4","author":"TL Poshusta","year":"2009","unstructured":"Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M (2009) Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE 4:e5169","journal-title":"PLoS ONE"},{"key":"10237_CR164","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41375-020-0800-6","volume":"35","author":"I Cuenca","year":"2021","unstructured":"Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, Onecha E, Lecumberri R, Prosper F, Ocio EM, Gonz\u00e1lez ME, Garc\u00eda de Coca A, De La Rubia J, Gironella M, Palomera L, Oriol A, Casanova M, Caba\u00f1as V, Taboada F, P\u00e9rez-Monta\u00f1a A, De Arriba F, Puig N, Carre\u00f1o-Tarragona G, Barrio S, Enrique de la Puerta J, Ramirez-Payer A, Krsnik I, Bargay JJ, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B, Martinez-Lopez J (2021) Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia 35:245\u2013249","journal-title":"Leukemia"},{"key":"10237_CR165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12104-020-09975-2","volume":"15","author":"T Pradhan","year":"2021","unstructured":"Pradhan T, Annamalai K, Sarkar R, Hegenbart U, Sch\u00f6nland S, F\u00e4ndrich M, Reif B (2021) Solid state NMR assignments of a human \u03bb-III immunoglobulin light chain amyloid fibril. Biomol NMR Assign 15:9\u201316","journal-title":"Biomol NMR Assign"},{"key":"10237_CR166","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1073\/pnas.87.17.6542","volume":"87","author":"M Eulitz","year":"1990","unstructured":"Eulitz M, Weiss DT, Solomon A (1990) Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci USA 87:6542\u20136546","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR167","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ki.2012.433","volume":"83","author":"MM Picken","year":"2013","unstructured":"Picken MM (2013) Non-light-chain immunoglobulin amyloidosis: time to expand or refine the spectrum to include light+heavy chain amyloidosis? Kidney Int 83:353\u2013356","journal-title":"Kidney Int"},{"key":"10237_CR168","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ki.2012.414","volume":"83","author":"SH Nasr","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Dispenzieri A, Buadi FK, Vrana JA, Theis JD, Dogan A, Leung N (2013) The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 83:463\u2013470","journal-title":"Kidney Int"},{"key":"10237_CR169","doi-asserted-by":"crossref","first-page":"e17999","DOI":"10.1097\/MD.0000000000017999","volume":"98","author":"Y Otaka","year":"2019","unstructured":"Otaka Y, Nakazato Y, Tsutsui T, Tamura J (2019) Cardiac involvement in heavy and light chain amyloidosis: a case report and literature review. Medicine (Baltimore) 98:e17999","journal-title":"Medicine (Baltimore)"},{"key":"10237_CR170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/16.11.673","volume":"16","author":"ED Eanes","year":"1968","unstructured":"Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16:673\u2013677","journal-title":"J Histochem Cytochem"},{"key":"10237_CR171","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1073\/pnas.1817538116","volume":"116","author":"E Rennella","year":"2019","unstructured":"Rennella E, Morgan GJ, Kelly JW, Kay LE (2019) Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proc Natl Acad Sci USA 116:854\u2013863","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR172","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41467-019-09032-0","volume":"10","author":"L Radamaker","year":"2019","unstructured":"Radamaker L, Lin YH, Annamalai K, Huhn S, Hegenbart U, Sch\u00f6nland SO, Fritz G, Schmidt M, F\u00e4ndrich M (2019) Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun 10:1103","journal-title":"Nat Commun"},{"key":"10237_CR173","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41467-021-21126-2","volume":"12","author":"L Radamaker","year":"2021","unstructured":"Radamaker L, Baur J, Huhn S, Haupt C, Hegenbart U, Schonland S, Bansal A, Schmidt M, Fandrich M (2021) Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nat Commun 12:875","journal-title":"Nat Commun"},{"key":"10237_CR174","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/13506120009146437","volume":"7","author":"LA Omtvedt","year":"2000","unstructured":"Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, Haavik S, Husby G, Sletten K, Hounsell EF (2000) Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 7:227\u2013244","journal-title":"Amyloid"},{"key":"10237_CR175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijbiomac.2020.10.194","volume":"166","author":"Y Abe","year":"2021","unstructured":"Abe Y, Shibata H, Oyama K, Ueda T (2021) Effect of O-glycosylation on amyloid fibril formation of the variable domain in the V\u03bb6 light chain mutant Wil. Int J Biol Macromol 166:342\u2013351","journal-title":"Int J Biol Macromol"},{"key":"10237_CR176","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","volume":"34","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Larson DR, Rajkumar SV, Kyle RA, Kumar SK, Kourelis T, Arendt B, Willrcih M, Dasari S, Murray D (2020) N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia 34:2749\u20132753","journal-title":"Leukemia"},{"key":"10237_CR177","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/13506120009146835","volume":"7","author":"FJ Stevens","year":"2000","unstructured":"Stevens FJ (2000) Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7:200\u2013211","journal-title":"Amyloid"},{"key":"10237_CR178","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-022-01599-w","volume":"36","author":"A Nevone","year":"2022","unstructured":"Nevone A, Girelli M, Mangiacavalli S, Paiva B, Milani P, Cascino P, Piscitelli M, Speranzini V, Cartia CS, Benvenuti P, Goicoechea I, Fazio F, Basset M, Foli A, Nanci M, Mazzini G, Caminito S, Sesta MA, Casarini S, Rognoni P, Lavatelli F, Petrucci MT, Olimpieri PP, Ricagno S, Arcaini L, Merlini G, Palladini G, Nuvolone M (2022) An N-glycosylation hotspot in immunoglobulin \u03ba light chains is associated with AL amyloidosis. Leukemia 36:2076\u20132085","journal-title":"Leukemia"},{"key":"10237_CR179","doi-asserted-by":"crossref","first-page":"14259","DOI":"10.1021\/bi7013773","volume":"46","author":"LH Connors","year":"2007","unstructured":"Connors LH, Jiang Y, Budnik M, Th\u00e9berge R, Prokaeva T, Bodi KL, Seldin DC, Costello CE, Skinner M (2007) Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry 46:14259\u201314271","journal-title":"Biochemistry"},{"key":"10237_CR180","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/19420862.2016.1160179","volume":"8","author":"T McSherry","year":"2016","unstructured":"McSherry T, McSherry J, Ozaeta P, Longenecker K, Ramsay C, Fishpaugh J, Allen S (2016) Cysteinylation of a monoclonal antibody leads to its inactivation. MAbs 8:718\u2013725","journal-title":"MAbs"},{"key":"10237_CR181","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/ars.2015.6317","volume":"23","author":"J Frijhoff","year":"2015","unstructured":"Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P (2015) Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 23:1144\u20131170","journal-title":"Antioxid Redox Signal"},{"key":"10237_CR182","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/ars.2016.6848","volume":"27","author":"L Diomede","year":"2017","unstructured":"Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M (2017) Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage. Antioxid Redox Signal 27:567\u2013582","journal-title":"Antioxid Redox Signal"},{"key":"10237_CR183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","volume":"2017","author":"G Merlini","year":"2017","unstructured":"Merlini G (2017) AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program 2017:1\u201312","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10237_CR184","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3389\/fimmu.2018.02328","volume":"9","author":"D Pilling","year":"2018","unstructured":"Pilling D, Gomer RH (2018) The development of serum amyloid P as a possible therapeutic. Front Immunol 9:2328","journal-title":"Front Immunol"},{"key":"10237_CR185","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","volume":"92","author":"GA Tennent","year":"1995","unstructured":"Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92:4299\u20134303","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR186","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nm0897-855","volume":"3","author":"M Botto","year":"1997","unstructured":"Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3:855\u2013859","journal-title":"Nat Med"},{"key":"10237_CR187","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1039\/C8CC04396E","volume":"54","author":"LM Blancas-Mejia","year":"2018","unstructured":"Blancas-Mejia LM, Misra P, Dick CJ, Cooper SA, Redhage KR, Bergman MR, Jordan TL, Maar K, Ramirez-Alvarado M (2018) Immunoglobulin light chain amyloid aggregation. Chem Commun (Camb) 54:10664\u201310674","journal-title":"Chem Commun (Camb)"},{"key":"10237_CR188","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","volume":"17","author":"A Martinez-Naharro","year":"2020","unstructured":"Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M (2020) Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol 17:413\u2013426","journal-title":"Nat Rev Cardiol"},{"key":"10237_CR189","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","volume":"7","author":"E Imperlini","year":"2017","unstructured":"Imperlini E, Gnecchi M, Rognoni P, Sabid\u00f2 E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Orr\u00f9 S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F (2017) Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep 7:15661","journal-title":"Sci Rep"},{"key":"10237_CR190","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107:4188\u20134193","journal-title":"Proc Natl Acad Sci USA"},{"key":"10237_CR191","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","volume":"291","author":"M Marin-Argany","year":"2016","unstructured":"Marin-Argany M, Lin Y, Misra P, Williams A, Wall JS, Howell KG, Elsbernd LR, McClure M, Ramirez-Alvarado M (2016) Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding. J Biol Chem 291:19813\u201319825","journal-title":"J Biol Chem"},{"key":"10237_CR192","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","volume":"119","author":"V Perfetti","year":"2012","unstructured":"Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G (2012) The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119:144\u2013150","journal-title":"Blood"},{"key":"10237_CR193","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","volume":"7","author":"CD Barrett","year":"2019","unstructured":"Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, Lafayette R, Fowler MB, Arai S, Schrier S, Witteles RM (2019) A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail 7:958\u2013966","journal-title":"JACC Heart Fail"},{"key":"10237_CR194","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40265-022-01830-z","volume":"83","author":"G Palladini","year":"2023","unstructured":"Palladini G, Milani P (2023) Diagnosis and treatment of AL amyloidosis. Drugs 83:203\u2013216","journal-title":"Drugs"},{"key":"10237_CR195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","volume":"106","author":"D Mohty","year":"2013","unstructured":"Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A (2013) Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106:528\u2013540","journal-title":"Arch Cardiovasc Dis"},{"key":"10237_CR196","first-page":"593460","volume":"2012","author":"K Bowen","year":"2012","unstructured":"Bowen K, Shah N, Lewin M (2012) AL-amyloidosis presenting with negative Congo red staining in the setting of high clinical suspicion: a case report. Case Rep Nephrol 2012:593460","journal-title":"Case Rep Nephrol"},{"key":"10237_CR197","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.acthis.2006.03.017","volume":"108","author":"M B\u00e9ly","year":"2006","unstructured":"B\u00e9ly M, Makovitzky J (2006) Sensitivity and specificity of Congo red staining according to Romh\u00e1nyi: comparison with Puchtler\u2019s or Bennhold\u2019s methods. Acta Histochem 108:175\u2013180","journal-title":"Acta Histochem"},{"key":"10237_CR198","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","volume":"54","author":"II Van Gameren","year":"2006","unstructured":"Van Gameren II, Hazenberg BPC, Bijzet J, Van Rijswijk MH (2006) Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015\u20132021","journal-title":"Arthritis Rheum"},{"key":"10237_CR199","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","volume":"38","author":"CC Quarta","year":"2017","unstructured":"Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD (2017) Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 38:1905\u20131908","journal-title":"Eur Heart J"},{"key":"10237_CR200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.carpath.2008.05.004","volume":"18","author":"AB Collins","year":"2009","unstructured":"Collins AB, Smith RN, Stone JR (2009) Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovasc Pathol 18:205\u2013216","journal-title":"Cardiovasc Pathol"},{"key":"10237_CR201","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8","volume":"82","author":"SV Rajkumar","year":"1998","unstructured":"Rajkumar SV, Gertz MA, Kyle RA (1998) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 82:1501\u20131505","journal-title":"Cancer"},{"key":"10237_CR202","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","volume":"97","author":"DP Steensma","year":"2001","unstructured":"Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE (2001) A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 97:2522\u20132523","journal-title":"Blood"},{"key":"10237_CR203","doi-asserted-by":"crossref","unstructured":"Zhang Q, Qiao Y, Yan D, Deng Y, Zhang M, Xu P (2020) Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: a case report. Open Med (Wars): 396\u2013402; \u00a9 2020 Qisi Zhang et al., published by De Gruyter","DOI":"10.1515\/med-2020-0125"},{"key":"10237_CR204","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","volume":"105","author":"G Palladini","year":"2005","unstructured":"Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949\u20132951","journal-title":"Blood"},{"key":"10237_CR205","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","volume":"109","author":"AD Wechalekar","year":"2007","unstructured":"Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457\u2013464","journal-title":"Blood"},{"key":"10237_CR206","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP (2007) High-dose Melphalan versus Melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083\u20131093","journal-title":"N Engl J Med"},{"key":"10237_CR207","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala V (2024) Systemic light chain amyloidosis. N Engl J Med 390:2295\u20132307","journal-title":"N Engl J Med"},{"key":"10237_CR208","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119:4391\u20134394","journal-title":"Blood"},{"key":"10237_CR209","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","volume":"44","author":"AT Nunes","year":"2017","unstructured":"Nunes AT, Annunziata CM (2017) Proteasome inhibitors: structure and function. Semin Oncol 44:377\u2013380","journal-title":"Semin Oncol"},{"key":"10237_CR210","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"10237_CR211","doi-asserted-by":"crossref","unstructured":"Allmeroth K, Horn M, Kroef V, Miethe S, M\u00fcller RU, Denzel MS (2021) Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia: 887\u2013892","DOI":"10.1038\/s41375-020-0989-4"},{"key":"10237_CR212","first-page":"238961","volume":"2012","author":"V Roy","year":"2012","unstructured":"Roy V (2012) Autologous stem cell transplant for AL amyloidosis. Bone Marrow Res 2012:238961","journal-title":"Bone Marrow Res"},{"key":"10237_CR213","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2677","volume":"37","author":"R Schwotzer","year":"2019","unstructured":"Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, St\u00fcssi G, Ghilardi G, Gerber B (2019) Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol 37:595\u2013600","journal-title":"Hematol Oncol"},{"key":"10237_CR214","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL (2020) Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 136:71\u201380","journal-title":"Blood"},{"key":"10237_CR215","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","volume":"323","author":"PN Hawkins","year":"1990","unstructured":"Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508\u2013513","journal-title":"N Engl J Med"},{"key":"10237_CR216","doi-asserted-by":"crossref","first-page":"355.e15","DOI":"10.1016\/j.amjmed.2005.08.043","volume":"119","author":"BP Hazenberg","year":"2006","unstructured":"Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, Jager PL (2006) Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 119:355.e15\u201324","journal-title":"Am J Med"},{"key":"10237_CR217","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.jproteome.7b00284","volume":"16","author":"M Dilillo","year":"2017","unstructured":"Dilillo M, Pellegrini D, Ait-Belkacem R, de Graaf EL, Caleo M, McDonnell LA (2017) Mass spectrometry imaging, laser capture microdissection, and LC-MS\/MS of the same tissue section. J Proteome Res 16:2993\u20133001","journal-title":"J Proteome Res"},{"key":"10237_CR218","doi-asserted-by":"crossref","unstructured":"Winter M, Tholey A, Kristen A, Rocken C (2017) MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis. Proteomics 17:1700236","DOI":"10.1002\/pmic.201700236"},{"key":"10237_CR219","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","volume":"119","author":"F Brambilla","year":"2012","unstructured":"Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, Verga L, Mauri P, Merlini G (2012) Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 119:1844\u20131847","journal-title":"Blood"},{"key":"10237_CR220","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41375-018-0308-5","volume":"33","author":"N Puig","year":"2019","unstructured":"Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, Garc\u00eda de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Caba\u00f1as V, Casanova M, Oriol A, Krsnik I, P\u00e9rez-Monta\u00f1a A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF (2019) Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia 33:1256\u20131267","journal-title":"Leukemia"},{"key":"10237_CR221","first-page":"004286","volume":"11","author":"F Laranjeira","year":"2024","unstructured":"Laranjeira F, Neves B, Bernardo P, do Rosario F, Fernandes O, Mendonca E, Catarino A (2024) A case of amyloid goitre in heavy chain amyloidosis: diagnostic challenges and clinical implications. Eur J Case Rep Intern Med. 11:004286","journal-title":"Eur J Case Rep Intern Med."},{"key":"10237_CR222","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/bmt.2014.288","volume":"50","author":"N Areethamsirikul","year":"2015","unstructured":"Areethamsirikul N, Masih-Khan E, Chu CM, Jimenez-Zepeda V, Reece DE, Trudel S, Kukreti V, Tiedemann R, Chen C (2015) CyBorD induction therapy in clinical practice. Bone Marrow Transplant 50:375\u2013379","journal-title":"Bone Marrow Transplant"},{"key":"10237_CR223","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","volume":"118","author":"JE Ward","year":"2011","unstructured":"Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O\u2019Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC (2011) Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood 118:6610\u20136617","journal-title":"Blood"},{"key":"10237_CR224","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.eclinm.2020.100361","volume":"23","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN (2020) Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. EClinicalMedicine 23:100361","journal-title":"EClinicalMedicine"},{"key":"10237_CR225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","volume":"145","author":"KN Shen","year":"2022","unstructured":"Shen KN, Fu WJ, Wu Y, Dong YJ, Huang ZX, Wei YQ, Li CR, Sun CY, Chen Y, Miao HL, Zhang YL, Cao XX, Zhou DB, Li J (2022) Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation 145:8\u201317","journal-title":"Circulation"},{"key":"10237_CR226","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1107\/S1399004714013455","volume":"70","author":"SE Kolstoe","year":"2014","unstructured":"Kolstoe SE, Jenvey MC, Purvis A, Light ME, Thompson D, Hughes P, Pepys MB, Wood SP (2014) Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC). Acta Crystallogr D Biol Crystallogr 70:2232\u20132240","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10237_CR227","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254\u2013259","journal-title":"Nature"},{"key":"10237_CR228","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373:1106\u20131114","journal-title":"N Engl J Med"},{"key":"10237_CR229","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","volume":"22","author":"A Wechalekar","year":"2022","unstructured":"Wechalekar A, Antoni G, Al Azzam W, Bergstrom M, Biswas S, Chen C, Cheriyan J, Cleveland M, Cookson L, Galette P, Janiczek RL, Kwong RY, Lukas MA, Millns H, Richards D, Schneider I, Solomon SD, Sorensen J, Storey J, Thompson D, van Dongen G, Vugts DJ, Wall A, Wikstrom G, Falk RH (2022) Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord 22:49","journal-title":"BMC Cardiovasc Disord"},{"key":"10237_CR230","doi-asserted-by":"crossref","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","volume":"7","author":"JS Wall","year":"2012","unstructured":"Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D (2012) AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE 7:e52686","journal-title":"PLoS ONE"},{"key":"10237_CR231","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","volume":"34","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Sch\u00f6nland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M (2016) First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 34:1097\u20131103","journal-title":"J Clin Oncol"},{"key":"10237_CR232","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"142","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schonland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G (2023) Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood 142:1208\u20131218","journal-title":"Blood"},{"key":"10237_CR233","doi-asserted-by":"crossref","unstructured":"Gertz MA, Sanchorawala V, Wechalekar AD, Ando Y, Koh Y, Nie C, Sheng XH, Conrad A, Kastritis E (2022) Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study. J Clin Oncol 40","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076"},{"key":"10237_CR234","first-page":"3831s","volume":"9","author":"A Solomon","year":"2003","unstructured":"Solomon A, Weiss DT, Wall JS (2003) Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11\u20131F4. Clin Cancer Res 9:3831s\u20133838s","journal-title":"Clin Cancer Res"},{"key":"10237_CR235","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A (2021) Phase 1a\/b study of monoclonal antibody CAEL-101 (11\u20131F4) in patients with AL amyloidosis. Blood 138:2632\u20132641","journal-title":"Blood"},{"key":"10237_CR236","doi-asserted-by":"crossref","first-page":"10127","DOI":"10.1182\/blood-2022-162597","volume":"140","author":"J Valent","year":"2022","unstructured":"Valent J, Liedtke M, Zonder JA, Tulchinskiy M, Udata C, Ramirez G, Szymaniak K, Catini J, Quarta CC (2022) 1-year results from a phase 2 study to determine safety and tolerability of treating patients with light-chain (AL) amyloidosis with cael-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia. Blood 140:10127\u201310128","journal-title":"Blood"},{"key":"10237_CR237","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2017.03.077","volume":"19","author":"M Rosenzweig","year":"2017","unstructured":"Rosenzweig M, Urak R, Walter M, Lim L, Sanchez JF, Krishnan A, Forman S, Wang X (2017) Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy 19:861\u2013866","journal-title":"Cytotherapy"},{"key":"10237_CR238","doi-asserted-by":"crossref","unstructured":"Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Dubnikov Sharon T, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME (2022) Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res","DOI":"10.1158\/1078-0432.c.6532965"},{"key":"10237_CR239","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","volume":"25","author":"M Emdin","year":"2023","unstructured":"Emdin M, Morfino P, Crosta L, Aimo A, Vergaro G, Castiglione V (2023) Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. Eur Heart J Suppl 25:B79\u2013B84","journal-title":"Eur Heart J Suppl"}],"container-title":["The Protein Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-024-10237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10930-024-10237-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-024-10237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:30:18Z","timestamp":1740137418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10930-024-10237-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":239,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10237"],"URL":"https:\/\/doi.org\/10.1007\/s10930-024-10237-6","relation":{},"ISSN":["1572-3887","1875-8355"],"issn-type":[{"value":"1572-3887","type":"print"},{"value":"1875-8355","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"24 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}